© Copyright Nostre Net
Market Synopsis:
The increase in the geriatric population is one of the
significant drivers of acute intermittent porphyria market. According to
reports, the aging population will almost double up by the end of 2050. Market
Research Future (MRFR) has revealed in its latest report that the Global Acute
Intermittent Porphyria Market Size will thrive steadily at 5.6 % during the
forecast period 2017-2023.
The risk factors associated with acute intermittent
porphyria, which include liver cancer (hepatocellular carcinoma), kidney
failure, neurological disorders, psychiatric issues, gastrointestinal problems,
urinary tract issues, etc. will accelerate the market expansion. The growth of
the market is also attributable to the increasing prevalence of the metabolic
disorders which is likely to increase further during the assessment period.
Get Sample Report @ https://www.marketresearchfuture.com/sample_request/4713
Competitive Dashboard:
The key players profiled by MRFR in its report include
Dahaner (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.),
Sysmex Corporation (Japan), ARKRAY, Inc. (Japan), ACON Laboratories, Inc.
(U.S.), and, F. Hoffmann-La Roche Ltd (Switzerland) among others. The players
strive to gain prominence in the market by devising and employing strategies
such as research & development, clinical trials, acquisitions & mergers,
innovative collaborations, agreements, etc.
Market Segmentation:
By diagnosis, the global acute intermittent porphyria market
has been segmented into blood test, urine test, serum test, DNA test, and
others.
By treatment, acute intermittent porphyria market is segmented
into gonadotropin-releasing hormone analogues, prophylactic hematin infusions,
and others.
By end user, the global acute intermittent porphyria market
has been segmented into hospitals & clinics, research centers, and others.
Regional Analysis:
By region, the acute intermittent porphyria market has been
segmented into North America & South America, Europe, Asia Pacific, and,
the Middle East & Africa. The North America & South America region will
generate maximum revenue from the market during the projection period. The
technological advancements integrated into the treatment of acute intermittent
porphyria is likely to accelerate revenue creation over the review period.
Other factors responsible for the growth of the market include increasing patient
with genetic metabolic disorders, rising healthcare expenditure, and increasing
government support for research & development. Furthermore, the
concentration of key players in the region coupled with increased research
& development activities will encourage the market growth and expansion.
Europe is the second largest market for acute intermittent
porphyria globally. The favorable factors supporting the market expansion in
the region are initiatives undertaken by the governments and the availability
of funds for research & development activities. The presence of developed
economies in the region is also likely to propel the market growth.
Access Report @ https://www.marketresearchfuture.com/reports/acute-intermittent-porphyria-market-4713
About US:
Market Research Future (MRFR), enable
customers to unravel the complexity of various industries through Cooked
Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research
Reports (3R), Continuous-Feed Research (CFR), and Market Research &
Consulting Services.
Contact us:
Market Research Future (part of
Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
The Wall